More than 2,000 lawsuits are now targeting the makers of Ozempic and Zepbound, with patients claiming the drugs caused dangerous and sometimes permanent health problems. The cases, consolidated in ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk revealed on Monday that US patients can now receive a month’s supply of Ozempic, a highly effective diabetes ...

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

As part of a new campaign, Whitley is partnering with Zepbound to break down the stigma surrounding obesity and inspire others to seek support and treatment.

Citing a $319 million budget shortfall, the state health department is implementing a minimum 3% rate reduction across all providers, the agency said.